Institute of Biomaterials & Biomedical Engineering, University of Toronto, 164 College Street, RS407, Toronto, Ontario, M5S 3G9, Canada.
Translational Biology & Engineering Program, Ted Rogers Centre for Heart Research, 661 University Avenue, Room 1433, Toronto, Ontario, M5G 1M1, Canada.
Heart Fail Rev. 2020 Mar;25(2):305-319. doi: 10.1007/s10741-019-09836-8.
Heart failure with preserved ejection fraction (HFpEF) is an increasingly prevalent phenotype affecting over half of today's heart failure patients. With no proven therapy and no universally accepted diagnostic guideline, many HFpEF patients continue to be misdiagnosed or underdiagnosed at the early stages until the disease has progressed much further along. It is extremely difficult to diagnose the HFpEF patient, because they have a normal ejection fraction and present with non-specific symptoms such as dyspnea or exercise intolerance. To provide greater specificity, the current diagnostic criteria mandate the presence of diastolic dysfunction, where myocardial relaxation is impaired and ventricular filling pressure is elevated as a result of a hypertrophic and stiff heart. Unfortunately, diastolic dysfunction reflects late-stage structural and functional changes and offers a very narrow window, if at all, for successful intervention. In this article, we review the imaging modalities used in the current diagnostic workflow for assessing HFpEF. We also describe the most up-to-date insight into its pathophysiological basis, which attributes systemic inflammation driven by comorbidities as the initiator of disease. With this extramyocardial perspective, we provide our recommendation on new imaging targets that extend beyond the heart to enable early, accurate diagnosis of HFpEF and allow an opportunity for treating this fatal condition.
射血分数保留型心力衰竭(HFpEF)是一种日益普遍的表型,影响了当今半数以上的心力衰竭患者。由于缺乏经过验证的治疗方法和普遍接受的诊断指南,许多 HFpEF 患者在疾病进一步发展之前,在早期仍被误诊或漏诊。HFpEF 患者的诊断极其困难,因为他们的射血分数正常,但表现出非特异性症状,如呼吸困难或运动不耐受。为了提供更大的特异性,目前的诊断标准要求存在舒张功能障碍,即心肌松弛受损,心室充盈压升高,原因是心脏肥厚和僵硬。不幸的是,舒张功能障碍反映了晚期的结构和功能变化,提供了一个非常狭窄的窗口,如果有的话,用于成功的干预。在本文中,我们回顾了目前用于评估 HFpEF 的诊断工作流程中使用的成像方式。我们还描述了其病理生理学基础的最新见解,该见解将合并症引起的系统性炎症归因于疾病的启动因素。从这个心肌外的角度出发,我们提出了新的成像靶点的建议,这些靶点超越了心脏,以实现 HFpEF 的早期、准确诊断,并为治疗这种致命疾病提供机会。